Combination therapy with an angiotensin converting enzyme inhibitor and an Angiotensin-II receptor antagonist for refractory essential hypertension

Western Journal of Medicine

Volumn 168, Issue 4, 1998, Pages 272-274

  Bisognano, John D ^a   Horwitz, Lawrence D ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LABETALOL; LOSARTAN; QUINAPRIL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE;

EID: 0031961045     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649-1654
2. Lessem J, Rucinska E, Vickers F, Espie J, Sromovsky J. Long-term enalapril - a new converting enzyme inhibitor - in the treatment of mild to moderate essential hypertension. Results of a worldwide multiclinic study. Clin Exper Hypertens 1985; 7:1515-1539
3. Ding Y, Chang S, Chou T. Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. J Human Hypertens 1995; 9:637-641
4. Plosker G, Sorkin E. Quinapril: a reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994; 48:227-252
5. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing hearts. Circ Res 1990; 66:883-890
6. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987; 149:1186-1192
7. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995; Suppl F:13F-19F
8. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, et al. Angiotensin-II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995, 96:1490-1498
9. Nunez E, Hosoya K, Susie D, Frohlich E. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997; 29:519-524
10. Meiracker A, Veld A, Admiraal P, Eck H, Boomsma R, Derkx F, Schalekamp M. Partial escape of angiotensin-converting enzyme inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992; 10:803-812
11. Azizi M, Chatellier G, Guyene T, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II: antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation 1995; 92:825-834